BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22717106)

  • 21. Ubiquitin specific peptidase 49 inhibits non-small cell lung cancer cell growth by suppressing PI3K/AKT signaling.
    Shen WM; Yin JN; Xu RJ; Xu DF; Zheng SY
    Kaohsiung J Med Sci; 2019 Jul; 35(7):401-407. PubMed ID: 31001918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN.
    Regina S; Valentin JB; Lachot S; Lemarié E; Rollin J; Gruel Y
    Clin Chem; 2009 Oct; 55(10):1834-42. PubMed ID: 19661141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. USP22 acts as an oncogene by regulating the stability of cyclooxygenase-2 in non-small cell lung cancer.
    Xiao H; Tian Y; Yang Y; Hu F; Xie X; Mei J; Ding F
    Biochem Biophys Res Commun; 2015 May; 460(3):703-8. PubMed ID: 25817787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long Noncoding RNA FAL1 Promotes Cell Proliferation, Invasion and Epithelial-Mesenchymal Transition Through the PTEN/AKT Signaling Axis in Non-Small Cell Lung Cancer.
    Pan C; Yao G; Liu B; Ma T; Xia Y; Wei K; Wang J; Xu J; Chen L; Chen Y
    Cell Physiol Biochem; 2017; 43(1):339-352. PubMed ID: 28854421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High levels of phosphatase and tensin homolog expression predict favorable prognosis in patients with non-small cell lung cancer.
    Li XB; Yang Y; Zhang HQ; Yue WT; Zhang TM; Lu BH; Li J; Liu Z; Wang QH; Gao Y; Hu AM; Zhang HM; Shi HL; Hu FB; Li BL
    Eur Rev Med Pharmacol Sci; 2015 Jun; 19(12):2231-9. PubMed ID: 26166648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.
    Stojsic J; Stankovic T; Stojkovic S; Milinkovic V; Dinic J; Milosevic Z; Milovanovic Z; Tanic N; Bankovic J
    Exp Mol Pathol; 2015 Feb; 98(1):27-32. PubMed ID: 25449334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer.
    Liu K; Chen HL; Gu MM; You QS
    Int J Clin Exp Pathol; 2015; 8(12):16081-8. PubMed ID: 26884885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. USP22 promotes NSCLC tumorigenesis via MDMX up-regulation and subsequent p53 inhibition.
    Ding F; Bao C; Tian Y; Xiao H; Wang M; Xie X; Hu F; Mei J
    Int J Mol Sci; 2014 Dec; 16(1):307-20. PubMed ID: 25547493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy.
    Shien K; Toyooka S; Ichimura K; Soh J; Furukawa M; Maki Y; Muraoka T; Tanaka N; Ueno T; Asano H; Tsukuda K; Yamane M; Oto T; Kiura K; Miyoshi S
    Lung Cancer; 2012 Jul; 77(1):162-7. PubMed ID: 22387005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer.
    Ni S; Wang H; Zhu X; Wan C; Xu J; Lu C; Xiao L; He J; Jiang C; Wang W; He Z
    Oncotarget; 2017 Jan; 8(5):8010-8021. PubMed ID: 28030829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreased H2B monoubiquitination and overexpression of ubiquitin-specific protease enzyme 22 in malignant colon carcinoma.
    Wang Z; Zhu L; Guo T; Wang Y; Yang J
    Hum Pathol; 2015 Jul; 46(7):1006-14. PubMed ID: 25971547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer.
    Ning J; Zhang J; Liu W; Lang Y; Xue Y; Xu S
    Eur J Histochem; 2012 Nov; 56(4):e46. PubMed ID: 23361242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma.
    Wang H; Li YP; Chen JH; Yuan SF; Wang L; Zhang JL; Yao Q; Li NL; Bian JF; Fan J; Yi J; Ling R
    Tumour Biol; 2013 Jun; 34(3):1635-9. PubMed ID: 23412977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical characterization of the mTOR pathway in stage-I non-small-cell lung carcinoma.
    Shin E; Choi CM; Kim HR; Jang SJ; Park YS
    Lung Cancer; 2015 Jul; 89(1):13-8. PubMed ID: 25936472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer.
    Lim WT; Zhang WH; Miller CR; Watters JW; Gao F; Viswanathan A; Govindan R; McLeod HL
    Oncol Rep; 2007 Apr; 17(4):853-7. PubMed ID: 17342327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma.
    Capodanno A; Camerini A; Orlandini C; Baldini E; Resta ML; Bevilacqua G; Collecchi P
    Hum Pathol; 2009 Oct; 40(10):1408-17. PubMed ID: 19428048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concurrent alteration of p16 and PTEN tumor suppressor genes could be considered as potential molecular marker for specific subgroups of NSCLC patients.
    Andjelkovic T; Bankovic J; Milosevic Z; Stojsic J; Milinkovic V; Pesic M; Ruzdijic S; Tanic N
    Cancer Biomark; 2011-2012; 10(6):277-86. PubMed ID: 22820083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VAOS, a novel vanadyl complexes of alginate saccharides, inducing apoptosis via activation of AKT-dependent ROS production in NSCLC.
    Zhou L; Yi Y; Yuan Q; Zhang J; Li Y; Wang P; Xu M; Xie S
    Free Radic Biol Med; 2018 Dec; 129():177-185. PubMed ID: 30223019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer.
    Yip PY; Cooper WA; Kohonen-Corish MR; Lin BP; McCaughan BC; Boyer MJ; Kench JG; Horvath LG
    J Clin Pathol; 2014 Apr; 67(4):333-40. PubMed ID: 24265323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased expression of USP22 is associated with disease progression and patient prognosis of salivary duct carcinoma.
    Piao S; Ma J; Wang W; Liu Y; Zhang M; Chen H; Guo F; Zhang B; Guo F
    Oral Oncol; 2013 Aug; 49(8):796-801. PubMed ID: 23664741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.